ArticleClinical and experimental nephrology2021

All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome.

Mana Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.